Through screening BC cells with CSC characteristics using the SRY-box 2 (SOX2) transcription factor, they illustrated metabolic overactivity in MCF-7 cells overexpressing SOX2, manifesting as enhanced glycolysis rate, and Tamoxifen resistance (15). This evidence concerns the gene SOX2 and breast cancer.